Baker Bros. Advisors LP Dumps Over 2.6 Million Celcuity Shares in Strategic Sell‑off Amid FDA Approval and Stock Slide

Insider Selling by Baker Bros. Advisors LP Signals a Strategic Realignment

On July 14, 2026, Baker Bros. Advisors LP executed a sizable sell of 261,368 shares of Celcuity Inc. at roughly $102.50 per share, reducing its stake from 442,940 to 181,572 shares. This transaction follows a prior sale of 2,838,632 shares on the same day, bringing the firm’s cumulative position to just 4,372,852 shares. While the trades represent a modest percentage of the company’s 19‑million‑share float, the timing—shortly after the FDA’s approval of Revtorpyk and amid a 22 % weekly slide in the stock—raises questions about how insiders view the company’s near‑term prospects.

What the Sell Might Mean for Investors

The price at which Baker Bros. sold its shares, slightly above the current trading price of $91.51, suggests the advisors were looking to lock in gains rather than capitulate to the recent downturn. In the context of a biotech with a negative P/E ratio of –27.79, the move may indicate confidence in the company’s ability to capitalize on its new approval and upcoming launch, while also seeking liquidity to fund other portfolio opportunities. For retail investors, the sale does not necessarily signal a bearish outlook; instead, it could reflect a portfolio rebalancing exercise rather than a fundamental reassessment of Celcuity’s pipeline.

Baker Bros. Advisors LP: A Historical Pattern of Opportunistic Trading

Baker Bros. Advisors LP’s transaction history illustrates a pattern of opportunistic buying and selling aligned with corporate milestones. In September 2025, the firm accumulated over 7.2 million shares, taking advantage of a relatively low share price (~$56–$58). By July 2026, the firm had trimmed its position by more than 80 % through two large sales, a move consistent with a “buy‑low, sell‑high” strategy. Unlike many institutional holders that maintain a long‑term stance, Baker Bros. appears to act swiftly to market movements, often timing transactions around FDA announcements, earnings releases, or significant share price volatility. This trading style suggests that the firm is less a passive steward of Celcuity’s growth and more a market‑aware participant looking for tactical opportunities.

Implications for Celcuity’s Future

The insider activity, coupled with the company’s recent FDA approval and a modest 1 % monthly rally, points to a mixed outlook. On the upside, the launch of Revtorpyk could generate a new revenue stream and validate Celcuity’s platform, potentially lifting the stock above its 52‑week low. On the downside, the firm’s significant selloffs could erode investor confidence, especially if other insiders follow suit. Moreover, the negative earnings multiple signals that the company is still in the R&D phase and not yet profitable, so the stock remains sensitive to clinical and regulatory developments.

Bottom Line for Investors

While Baker Bros. Advisors LP’s recent sales may raise eyebrows, they appear to be part of a broader, opportunistic strategy rather than a definitive statement on Celcuity’s trajectory. Investors should monitor upcoming milestones—particularly the Q3 launch of Revtorpyk, the supplemental filing for PIK3CA‑mutant patients, and any further FDA actions—alongside any new insider transactions. A nuanced view that balances the company’s clinical promise with its current valuation metrics will be key to navigating this biotech’s next chapter.